Duoduo Pharmaceutical Co. Ltd.

Primary Objective: This study used fenelazol tablets (10 mg) manufactured by Duoduo Pharmaceutical Co., Ltd. as the test formulation and, in accordance with the relevant regulations for bioequivalence studies, used fenelazol tablets [10 mg, trade name: Kerendia®] manufactured by Bayer AG as the reference formulation to evaluate the bioequivalence of the test and reference formulations after administration under fasting conditions. Secondary Objective: To observe the safety of the test and reference formulations, fenelazol tablets [Kerendia®], in healthy trial participants.

Primary objective: To evaluate the bioequivalence of a single oral administration of the test formulation ticagrelor tablets (90 mg, manufactured by Duoduo Pharmaceutical Co., Ltd.) and the reference formulation ticagrelor tablets (90 mg, manufactured by AstraZeneca) under fasting conditions. Secondary objective: To evaluate the safety of the test and reference formulations (90 mg) in healthy adult participants in China.

Primary objective: To evaluate the bioequivalence of calcium dobesilate capsules 0.5 g (test formulation) manufactured by Doxium Pharmaceutical Co., Ltd. and calcium dobesilate capsules 0.5 g (trade name: Doxium; reference formulation) manufactured by Klocke Pharma Service in healthy Chinese participants under fasting or postprandial conditions; Secondary objective: To observe the safety of the test and reference formulations of calcium dobesilate capsules in healthy Chinese participants.